Coccidioidomycosis

John H. Galgiani, Neil M. Ampel, Janis E. Blair, Antonino Catanzaro, Royce H. Johnson, David A. Stevens, Paul L. Williams

Research output: Contribution to journalReview article

456 Scopus citations

Abstract

Management of coccidioidomycosis first involves recognizing that a coccidioidal infection exists, defining the extent of infection, and identifying host factors that predispose to disease severity. After these assessments, patients with localized acute pulmonary infections and no risk factors for complications often require only periodic reassessment to demonstrate resolution of their self-limited process. On the other hand, patients with extensive spread of infection or who are at high risk of complications because of immunosuppression or other preexisting factors require a variety of treatment strategies that may include antifungal drug therapy, surgical debridement, or a combination of both. Azole antifungals, primarily fluconazole and itraconazole, have replaced amphotericin B as initial therapy for most chronic pulmonary or disseminated infections. Amphotericin B is now usually reserved for patients with respiratory failure due to infection with Coccidioides species, those with rapidly progressive coccidioidal infections, or women during pregnancy. Therapy often ranges from many months to years in duration, and in some patients, lifelong suppressive therapy is needed to prevent relapses.

Original languageEnglish (US)
Pages (from-to)1217-1223
Number of pages7
JournalClinical Infectious Diseases
Volume41
Issue number9
DOIs
StatePublished - Nov 1 2005

    Fingerprint

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Galgiani, J. H., Ampel, N. M., Blair, J. E., Catanzaro, A., Johnson, R. H., Stevens, D. A., & Williams, P. L. (2005). Coccidioidomycosis. Clinical Infectious Diseases, 41(9), 1217-1223. https://doi.org/10.1086/496991